ENTRY       D11550                      Drug
NAME        Bimekizumab (USAN/INN);
            Bimekizumab (genetical recombination) (JAN);
            Bimzelx (TN)
FORMULA     C6552H10132N1750O2029S42
EXACT_MASS  147137.1715
MOL_WEIGHT  147227.7921
SEQUENCE    (Heavy chain)
            EVQLVESGGG LVQPGGSLRL SCAASGFTFS DYNMAWVRQA PGKGLEWVAT ITYEGRNTYY
            RDSVKGRFTI SRDNAKNSLY LQMNSLRAED TAVYYCASPP QYYEGSIYRL WFAHWGQGTL
            VTVSSASTKG PSVFPLAPSS KSTSGGTAAL GCLVKDYFPE PVTVSWNSGA LTSGVHTFPA
            VLQSSGLYSL SSVVTVPSSS LGTQTYICNV NHKPSNTKVD KKVEPKSCDK THTCPPCPAP
            ELLGGPSVFL FPPKPKDTLM ISRTPEVTCV VVDVSHEDPE VKFNWYVDGV EVHNAKTKPR
            EEQYNSTYRV VSVLTVLHQD WLNGKEYKCK VSNKALPAPI EKTISKAKGQ PREPQVYTLP
            PSRDELTKNQ VSLTCLVKGF YPSDIAVEWE SNGQPENNYK TTPPVLDSDG SFFLYSKLTV
            DKSRWQQGNV FSCSVMHEAL HNHYTQKSLS LSPGK
            (Light chain)
            AIQLTQSPSS LSASVGDRVT ITCRADESVR TLMHWYQQKP GKAPKLLIYL VSNSEIGVPD
            RFSGSGSGTD FRLTISSLQP EDFATYYCQQ TWSDPWTFGQ GTKVEIKRTV AAPSVFIFPP
            SDEQLKSGTA SVVCLLNNFY PREAKVQWKV DNALQSGNSQ ESVTEQDSKD STYSLSSTLT
            LSKADYEKHK VYACEVTHQG LSSPVTKSFN RGEC
            (Disulfide bridge: H22-H96, H152-H208, H228-L214, H234-H'234, H237-H'237, H269-H329, H375-H433, H'22-H'96, H'152-H'208, H'228-L'214, H'269-H'329, H'375-H'433, L23-L88, L134-L194, L'23-L'88, L'134-L'194)
  TYPE      Peptide
CLASS       Immunological agent
             DG02019  Interleukin inhibitor
REMARK      Therapeutic category: 3999
            ATC code: L04AC21
            Product: D11550<JP>
EFFICACY    Antipsoriatic, Anti-IL-17A/IL-17F antibody
  DISEASE   Plaque psoriasis [DS:H01656]
  TYPE      Monoclonal antibody
COMMENT     Treatment of moderate to severe plaque psoriasis
TARGET      IL17A [HSA:3605] [KO:K05489]
            IL17F [HSA:112744] [KO:K05494]
  PATHWAY   hsa04060(112744+3605)  Cytokine-cytokine receptor interaction
            hsa04657(112744+3605)  IL-17 signaling pathway
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
              L04 IMMUNOSUPPRESSANTS
               L04A IMMUNOSUPPRESSANTS
                L04AC Interleukin inhibitors
                 L04AC21 Bimekizumab
                  D11550  Bimekizumab (USAN/INN) &lt;JP&gt;
            Therapeutic category of drugs in Japan [BR:br08301]
             3  Agents affecting metabolism
              39  Other agents affecting metabolism
               399  Miscellaneous
                3999  Others
                 D11550  Bimekizumab (USAN/INN); Bimekizumab (genetical recombination) (JAN)
            Drug groups [BR:br08330]
             Immunological agent
              DG02019  Interleukin inhibitor
               D11550  Bimekizumab
            Drug classes [BR:br08332]
             Immunological agent
              DG02019  Interleukin inhibitor
               D11550  Bimekizumab
            Target-based classification of drugs [BR:br08310]
             Cytokines and receptors
              Cytokines
               Interleukins
                IL17A
                 D11550  Bimekizumab (USAN/INN) &lt;JP&gt;
                IL17F
                 D11550  Bimekizumab (USAN/INN) &lt;JP&gt;
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D11550
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D11550
            New drug approvals in Japan [br08318.html]
             Drugs with new active ingredients
              D11550
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D11550
DBLINKS     CAS: 1418205-77-2
            PubChem: 384585526
///
